The NUSeq Core Facility, in collaboration with Illumina, provided a total of $55,363 to 25 Northwestern research projects via a Pilot Project Program launched in November 2017. The goal of the program was to provide seed money to investigators to generate preliminary data for grant proposal submissions. Due to the overwhelming response to the call for applications, Illumina increased their support to the current level from the originally planned $15,000.
Investigators from the Feinberg School of Medicine, McCormick School of Engineering & Applied Science, and the Weinberg College of Arts and Sciences received pilot funding for a range of research topics, including:
- Cancer biology
- Developmental biology
- Environmental microbial metagenomics
- Infectious disease
- Stem cells
- Liver, skin, and kidney diseases
The pilot fund awarded for each project will be used by the NUSeq Core Facility to provide next-gen sequencing data generation services on the Illumina HiSeq and MiSeq sequencers. Using the preliminary results generated from this program, scientists will then compete for a combined $33.5M in research funding from the NIH, NSF, DoD, DOE, Environmental Research & Education Foundation, and the US-Israel Binational Science Foundation. NUSeq will continue to support investigators awarded funding by agencies with genome technology and bioinformatics analysis.
About NUSeq Core Facility
The NUSeq Core is a shared resource facility that serves investigators at Northwestern University, affiliated institutions, and external academic and commercial organizations. The facility provides a wide range of next generation sequencing and microarray services, including bioinformatics analyses. Other services include DNA extraction, cell line authentication, DNA/RNA quality control, and Sanger sequencing.
Illumina is the leading provider of next generation sequencing technologies for biomedical research. Next-gen sequencers offered by Illumina generate highly accurate sequencing reads for a wide range of applications, from multi-whole-genome analyses, transcriptome, to highly targeted analyses such as cancer gene panel sequencing. The company is the global leader and a mjor driving force in the precision medicine arena. NUSeq operates a fleet of all major next-gen sequencers manufactured by Illumina.